Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay
Quantification of CD44v6 and EGFR expression in head and neck squamous cell carcinomas using a single-dose radioimmunoassay
复制标题
DOI：
10.1159/000110898
复制
发表时间：
2007-01-01
期刊：
影响因子：
--
通讯作者：
Anniko, Matti
中科院分区：
文献类型：
--
作者：
Nestor, Marika;Ekberg, Tomas;Anniko, Matti
背景：随着肿瘤靶向研究的不断发展，迫切需要寻找合适的分子靶点。在本研究中，使用单剂量（SD）放射免疫分析法定量检测头颈部鳞状细胞癌（HNSCC）患者样本中CD44v6和EGFR的表达。方法：首先验证i -125嵌合单克隆抗体（cMAb） U36和I-125-cMAb西图昔单抗的SD放射免疫测定，然后定量患者样品中其靶抗原分子CD44v6和EGFR的表达。结果与免疫组织化学染色比较。结果：SD法提供了所研究分子靶点的敏感定量值，与免疫组化（IHC）结果基本一致。结果表明，在所分析的肿瘤样本中，CD44v6 （0.2 ~ 20 nmol/ μ g膜）的表达普遍高于EGFR （0.6 ~ 2.3 nmol/ μ g膜），平均对应于每个细胞70万个和9万个抗原分子。结论：SD放射免疫测定方法简单、可靠，可在少量（50 mg）组织中进行。这种检测方法可能成为个性化癌症治疗领域的有用工具，并可作为免疫组化的补充。在研究的肿瘤中，CD44v6的表达水平通常高于EGFR，这可能表明它更容易被单克隆抗体靶向。版权所有(c) 2007 S. Karger AG，巴塞尔。
Background: In the growing field of tumor targeting, there is an urgent need to profile suitable molecular targets. In this study, CD44v6 and EGFR expression was quantified in samples of patients with head and neck squamous cell carcinoma (HNSCC) using a single-dose (SD) radioimmunoassay. Methods: The SD radioimmunoassay using I-125-chimeric monoclonal antibody (cMAb) U36 and I-125-cMAb cetuximab was first validated and then applied to quantify the expression of their target antigen molecules, CD44v6 and EGFR, in patient samples. Results were compared to immunohistochemical staining. Results: The SD assay provided sensitive quantitative values of the molecular targets studied, generally agreeing with the immunohistochemistry (IHC) results. The results indicated that expression of CD44v6 (0.2- 20 nmol/mu g membrane) was generally higher than that of EGFR (0.6-2.3 nmol/mu g membrane) in the tumor samples analyzed, which corresponded to an average of 700,000 and 90,000 antigen molecules per cell, respectively. Conclusions: The SD radioimmunoassay is simple, reliable, and can be performed on a small amount (50 mg) of tissue. This assay could be a useful tool in the growing field of personalized cancer therapy, and can be used as a complement to IHC. In the tumors studied, CD44v6 was generally expressed at a higher level than EGFR, which might suggest that it could be more readily targeted by MAbs. Copyright (c) 2007 S. Karger AG, Basel.